Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger (Nasdaq: SDGR) announces the retirement of CFO Joel Lebowitz, effective February 28, 2022. Lebowitz, who played a key role in the company’s transition to public status and financial growth, will assist in the search for his successor. CEO Ramy Farid commended his contributions, stating that Schrödinger is well-capitalized and positioned for future success. The company reaffirms its full-year 2021 financial guidance, previously announced on November 10, 2021.
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to 14 new employees totaling 42,850 shares on December 16, 2021, as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $35.04 per share, reflecting the closing stock price on that date. Each option vests over four years, with 25% vesting after the first year and the remainder monthly over the next three years. Schrödinger leverages its physics-based software platform for drug and material discovery, serving clients in over 70 countries.
Schrödinger, Inc. (SDGR) presented promising preclinical data on its MALT1 inhibitors for treating B-cell lymphomas at the American Society of Hematology Annual Meeting. The data indicate strong anti-tumor activity across various models and highlight the combination potential with existing therapies like ibrutinib. The company aims to submit an Investigational New Drug Application to the FDA in the first half of 2022, potentially expanding treatment options for patients with specific B-cell lymphomas, including ABC-DLBCL and MCL.
Schrödinger (Nasdaq: SDGR) announced its participation in several upcoming investor conferences. Notable events include the 33rd Annual Piper Sandler Virtual Healthcare Conference, the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, and the BMO 2021 Growth & ESG Conference on December 7, 2021. Management will also engage in one-on-one meetings during the Berenberg Discover AI Seminar 2021 on December 1. Interested parties can access both live and archived webcasts through the investors section of Schrödinger's website.
Schrödinger (Nasdaq: SDGR) has secured a
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options to purchase 7,250 shares of common stock to four newly hired employees on
Schrödinger, Inc. (Nasdaq: SDGR) reported third-quarter 2021 revenue of $29.9 million, up 16% year-over-year. Software revenue was $24.3 million, reflecting growth despite the impact of previous multi-year contracts. Drug discovery revenue increased to $5.6 million, driven by a collaboration with Bristol Myers Squibb. However, gross profit fell to $11.1 million, down from $15.3 million last year. Operating expenses surged to $45.8 million, leading to a net loss of $35 million. The company maintains a full-year revenue outlook of $124 million to $134 million.
Schrödinger (Nasdaq: SDGR) announced its participation in the Jefferies London Healthcare Conference, with a pre-recorded fireside chat presentation accessible on November 18, 2021, after 8:00 a.m. GMT. The webcast will be available on their website and archived for about 14 days. The company is recognized for its physics-based software platform that accelerates the discovery of therapeutics and materials, aiding biopharmaceutical firms and academic institutions globally. Founded in 1990, Schrödinger operates in over 70 countries with a team of over 500 employees.
Schrödinger, Inc. (Nasdaq: SDGR) announced new preclinical data on its small-molecule MALT1 inhibitors, to be presented at the American Society of Hematology's Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. MALT1 inhibitors are a promising therapeutic route for certain non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia (CLL). The lead MALT1 inhibitor is expected to enter clinical trials next year. The presentation will cover characterization details, which may enhance investor interest and highlight the company's innovative drug discovery approach.
Schrödinger (Nasdaq: SDGR) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results. The call will provide an update on the company's business and can be accessed via its website's investor section. Schrödinger specializes in a physics-based software platform aimed at revolutionizing therapeutic and material discovery, offering faster and cost-effective solutions for its clients in multiple sectors.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
